Efficacy and safety of darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and a prostate-specific antigen doubling time (PSADT) > and <= 6 months.

K. Schlack, M. R. Smith, N. D. Shore, T. L. J. Tammela, A. Ulys, E. Vjaters, S. Polyakov, M. Jievaltas, M. Luz, B. Alekseev, I. Kuss, M. -A. Le Berre, A. Snapir, T. Sarapohja, K. Fizazi

Research output: Contribution to journalMeeting Abstractpeer-review

Fingerprint

Dive into the research topics of 'Efficacy and safety of darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and a prostate-specific antigen doubling time (PSADT) > and <= 6 months.'. Together they form a unique fingerprint.

Medicine & Life Sciences